Ladarixin
| Code | Size | Price |
|---|
| TAR-T32533-50mg | 50mg | £771.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Ladarixin is a dual, non-competitive allosteric inhibitor of CXCR1 and CXCR2 interleukin8 (IL-8a and IL-8b, respectively). The efficacy of CXCR1/2 inhibition prevents inflammation and autoimmune-mediated islet damage.
CAS:
849776-05-2
Formula:
C11H12F3NO6S2
Molecular Weight:
375.33
Purity:
0.98
SMILES:
C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1
References
1. Citro A, Valle A, Cantarelli E, Mercalli A, Pellegrini S, Liberati D, Daffonchio L, Kastsiuchenka O, Ruffini PA, Battaglia M, Allegretti M, Piemonti L. CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice. Diabetes. 2015 Apr;64(4):1329-40. doi: 10.2337/db14-0443. Epub 2014 Oct 14. PubMed PMID: 25315007.
2. Carreira EU, Carregaro V, Teixeira MM, Moriconi A, Aramini A, Verri WA Jr, Ferreira SH, Cunha FQ, Cunha TM. Neutrophils recruited by CXCR1/2 signalling mediate post-incisional pain. Eur J Pain. 2013 May;17(5):654-63. doi: 10.1002/j.1532-2149.2012.00240.x. Epub 2012 Nov 7. PubMed PMID: 23132735.